EUCTR2007-000442-12-BE进行中（未招募）不适用
A non-comparative open pilot trial to assess the safety and pharmacokinetics of up to three single doses of AERUMAB 11 in patients with hospital acquired pneumonia caused by serotype O11 P. aeruginosa - NA
Kenta Biotech0 个研究点目标入组 20 人开始时间: 2008年9月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female = 18 years of age
- •2.Female patients sterilised, hysterectomised, post-menopausal, or negative pregnancy test at screening evaluation.
- •3.Patients under intensive care management with hospital-acquired pneumonia
- •4.In intubated patients confirmed microbiological diagnosis of P. aeruginosa serotype O11 HAP by lower respiratory tract specimen (BAL or miniBAL) with equal or greater to 1x104 CFU/mL, or between 1x10^3 and 1x10^4 CFU/ml if the patient is under antibiotic treatment, and presence of a new or progressing pulmonary infiltrate, plus one of the three following criteria: a) fever greater than 38oC, b) WBC greater than 10,000/mm3, or c) purulent sputum
- •in non-intubated patients confirmed microbiological diagnosis of P. aeruginosa serotype O11 HAP by endotracheal aspirate (ETA) with equal or greater to 1x106 CFU/mL, and modified clinical pulmonary infection score (CPIS) higher than 6 points
- •Note: Serotyping may either be done with conventional microbiology/serology or PCR
- •5.Patient is expected to survive longer than 72 hours
- •6.Written informed consent provided by the patient or by the relatives or the designated trusted person
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Use of any investigational drug within 30 days preceding the first dose of AERUMAB 11, or planned use during the study and safety follow-up periods
- •2.Existence of any surgical or medical condition that might render the patient unduly susceptible to possible toxicity from the monoclonal antibody, including septic shock with unstable hemodynamics, as defined by a systolic blood pressure below 90 mmHg, despite vasopressor administration of epinephrine / norepinephrine at a dosage of greater than 0.1 µg/kg/min or dopamine at a dosage of greater 15 µg/kg/min), and presence of clinically relevant disseminated intravascular coagulation (overt DIC, as defined by a score of 5 or more using the scoring system proposed by the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the ISTH) [ ]
- •3.Patients with a known complement deficiency associated with systemic lupus erythematosus (SLE), paroxysmal nocturnal hemoglobinuria (PNH), hereditary angioedema (HAE), membranoproliferative glomerulonephritis, collagen vascular disease, autoimmune hepatitis, primary biliary cirrhosis, scleroderma, or recurrent Neisserial infections
- •4.Confirmed Human Immunodeficiency Virus (HIV) infection
- •5.Transplant patients and/or simultaneous treatment with systemic immuno-suppressive drugs. However, prednisone or prednisolone are allowed
- •6.Patients with a known liver function deficiency, e.g. associated with liver cirrhosis (Child Pugh B or C) or acute hepatitis
- •7.Administration of poly- or mono-immunoglobulins within the three months preceding the first dose of study drug or planned administration during the study period
- •8.Neutropenic patients (absolute neutrophil count < 1000 cells per microlitre)
研究者
相似试验
进行中（未招募）
1 期
A non-comparative open pilot trial to assess the safety and pharmacokinetics of up to three single doses of AERUMAB 11 in patients with ventilator associated pneumonia caused by serotype O11 P. aeruginosa - NAEUCTR2007-000442-12-FRKenta Biotech Ltd15
进行中（未招募）
不适用
A non-comparative open pilot trial to assess the safety and pharmacokinetics of up to three single doses of AERUMAB 11 in patients with ventilator associated pneumonia caused by serotype O11 P. aeruginosa - AERUMAB 11EUCTR2007-000442-12-GRKenta Biotech Ltd40
招募中
2 期
To assess by a randomised,pilot study which of the two treatment regimens i.e. Rituximab infusion or Dexamethasone pulse therapy is more efficacious in the treatment of pemphigus vulgaris and relationship of various immunological parameters in skin and bloodCTRI/2018/12/016531DR SUJAY KHANDPUR
尚未招募
Unknown
Study Comparing Two Heart Monitoring DevicesCTRI/2024/04/065617itto Denko Asia Technical Centre Pte Ltd,
招募中
Unknown
A trial to assess the short-term efficacy of spectacle films and contact lenses in myopic childreEye - Diseases / disorders of the eyeMyopiaACTRN12623000319673nthalmic Pty Ltd60